Controlled release ibuprofen-poloxamer gel for epidural use - A pharmacokinetic study using microdialysis in pigs.
In order to avoid the risks of sideeffects of epidural local anesthetics and opioids, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) epidurally would be an interesting option of analgesic therapy. The fairly short duration of action of spinally administered NSAIDs, e.g., ibuprofen, may be prolonged by using controlled release poloxamer gel formulation. Using a microdialysis technique we studied the epidural and intrathecal pharmacokinetics of ibuprofen after its epidural administration as a poloxamer 407 formulation or a solution formulation. In addition, plasma ibuprofen concentrations were analyzed from central venous blood samples. Ibuprofen concentrations in the epidural space were significantly higher and longer lasting after the epidural gel injection compared with the epidural solution injection. The epidural AUC of ibuprofen was over threefold greater after epidural ibuprofen gel injection compared with the ibuprofen solution injection (p<0.001). The systemic absorption of ibuprofen from 25% poloxamer 407 gel was very low. The in situ forming poloxamer gel acted as a reservoir allowing targeted ibuprofen release at the epidural injection site and restricted ibuprofen molecules to a smaller spinal area. Ibuprofen diffusion from the epidural space to the intrathecal space was steady and prolonged. These results demonstrate that the use of epidurally injectable poloxamer gel can increase and prolong ibuprofen delivery from epidural space to the CSF enhancing thus ibuprofen entry into the central neuroaxis for spinal analgesia. Further toxicological and dose-finding studies are justified.
Faculty of Pharmacy, University of Helsinki, Finland; Department of Anesthesiology, University of Washington, Seattle, USA. Electronic address: anne.paavola@helsinki.fi.
Anne
A
Paavola
Department of Anesthesiology, University of Washington, Seattle, USA.
Christopher M
CM
Bernards
Department of Anesthesiology, Helsinki University Central Hospital, Finland.
Per H
PH
Rosenberg
D000779:Anesthetics, Local / Q000008:administration & dosage; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D019540:Area Under Curve; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D005782:Gels / Q000737:chemistry*; D007052:Ibuprofen / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry; D007268:Injections, Epidural; D007700:Kinetics; D017551:Microdialysis; D020442:Poloxamer / Q000737:chemistry*; D012492:Salts / Q000737:chemistry; D012996:Solutions; D013552:Swine; D014783:Viscosity
D000779:Anesthetics, Local; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D005782:Gels; D012492:Salts; D012996:Solutions; D020442:Poloxamer; D007052:Ibuprofen
Controlled release; Epidural; Ibuprofen·Na; Injectable; Intrathecal; Microdialysis; Poloxamer 407 gel